Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)

Go back to Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
(NASDAQ: GMDA) Delayed: 6.83 +0.05 (0.74%)
Previous Close $6.78    52 Week High
Open $6.77    52 Week Low
Day High $7.03    P/E N/A 
Day Low $6.75    EPS
Volume 196,163